Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1981 Jul;33(1):22–28. doi: 10.1128/iai.33.1.22-28.1981

Complement-fixing antibody to the AG-4 antigen in herpes simplex virus type 2-infected patients.

M Arsenakis, J T May
PMCID: PMC350647  PMID: 6266964

Abstract

Sera collected from confirmed herpes simplex virus type 2 (HSV-2) patients were found to be devoid of complement-fixing antibody to the AG-4 antigen at the time of the herpes lesion outbreak in 10 out of 13 cases. However, 1 to 4 weeks after HSV-2 lesion appearance, 28 out of 30 patients acquired complement-fixing antibody to the AG-4 antigen. The sera of these patients contained immunoglobulin M antibody activity and the ability to immunoprecipitate a 160,000-molecular weight early HSV-2 antigen (the AG-4 antigen). Also, these sera were used to show that a variety of anti-herpes virus compounds had a negligible effect on AG-4 production in HSV-2-infected HEp-2 cells. The majority of the compounds tested (including acycloguanosine and phosphonoformate) are known to inhibit late antigen production, suggesting that the AG-4 antigen is an early antigen. It is probably an immediate early antigen (alpha) as it is formed in the presence of cycloheximide and actinomycin D, a treatment which is used to accumulate alpha proteins.

Full text

PDF
22

Images in this article

25Image
on p.25

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arsenakis M., Georgiou G. M., Welsh J. K., Cauchi M. N., May J. T. AG-4 complement-fixing antibodies in cervical cancer and herpes-infected patients using local herpes simplex virus type 2. Int J Cancer. 1980 Jan 15;25(1):67–71. doi: 10.1002/ijc.2910250109. [DOI] [PubMed] [Google Scholar]
  2. Aurelian L., Schumann B., Marcus R. L., Davis H. J. Antibody to HSV-2 induced tumor specific antigens in serums from patients with cervical carcinoma. Science. 1973 Jul 13;181(4095):161–164. doi: 10.1126/science.181.4095.161. [DOI] [PubMed] [Google Scholar]
  3. Devoret R. Bacterial tests for potential carcinogens. Sci Am. 1979 Aug;241(2):40–49. doi: 10.1038/scientificamerican0879-40. [DOI] [PubMed] [Google Scholar]
  4. Gerna G., Cereda P. M., Cattaneo E., Achilli G., Gerna M. T. Antibody to early antigens of varicella-zoster virus during varicella and zoster. J Infect Dis. 1979 Jul;140(1):33–41. doi: 10.1093/infdis/140.1.33. [DOI] [PubMed] [Google Scholar]
  5. Griffiths P. D., Buie K. J., Heath R. B. Persistence of high titre antibodies to the early antigens of cytomegalovirus in pregnant women. Arch Virol. 1980;64(4):303–309. doi: 10.1007/BF01320615. [DOI] [PubMed] [Google Scholar]
  6. Heise E. R., Kucera L. S., Raben M., Homesley H. Serological response patterns to herpes virus type 2 early and late antigens in cervical carcinoma patients. Cancer Res. 1979 Oct;39(10):4022–4026. [PubMed] [Google Scholar]
  7. Kawana T., Sakamoto S., Kasamatsu T., Aurelian L. Frequency of anti-AG-4 antibody in patients with uterine cervical cancer and controls. Gan. 1978 Aug;69(4):589–591. [PubMed] [Google Scholar]
  8. Medappa K. C., McLean C., Rueckert R. R. On the structure of rhinovirus 1A. Virology. 1971 May;44(2):259–270. doi: 10.1016/0042-6822(71)90258-3. [DOI] [PubMed] [Google Scholar]
  9. Notter M. F., Docherty J. J. Comparative diagnostic aspects of herpes simplex virus tumor-associated antigens. J Natl Cancer Inst. 1976 Sep;57(3):483–488. doi: 10.1093/jnci/57.3.483. [DOI] [PubMed] [Google Scholar]
  10. Pereira L., Wolff M. H., Fenwick M., Roizman B. Regulation of herpesvirus macromolecular synthesis. V. Properties of alpha polypeptides made in HSV-1 and HSV-2 infected cells. Virology. 1977 Apr;77(2):733–749. doi: 10.1016/0042-6822(77)90495-0. [DOI] [PubMed] [Google Scholar]
  11. Rawls W. E., Bacchetti S., Graham F. L. Relation of Herpes simplex viruses to human malignancies. Curr Top Microbiol Immunol. 1977;77:71–95. doi: 10.1007/978-3-642-66740-4_3. [DOI] [PubMed] [Google Scholar]
  12. Reinhardt A., Sands J. A., Snipes W. Virucidal activity of retinal. Antimicrob Agents Chemother. 1979 Sep;16(3):421–423. doi: 10.1128/aac.16.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Strnad B. C., Aurelian L. Proteins of herpesvirus type 2. II. Studies demonstrating a correlation between a tumor-associated antigen (AG-4) and a virion protein. Virology. 1976 Aug;73(1):244–258. doi: 10.1016/0042-6822(76)90078-7. [DOI] [PubMed] [Google Scholar]
  14. Welsh J. K., Skurrie I. J., May J. T. Use of Semliki forest virus to identify lipid-mediated antiviral activity and anti-alphavirus immunoglobulin A in human milk. Infect Immun. 1978 Feb;19(2):395–401. doi: 10.1128/iai.19.2.395-401.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES